文献速递免疫规划

与SARS-CoV-2 BNT162b2 mRNA疫苗抗体应答强度相关的免疫学特征

Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2.
PubMed 文献 · Vaccine · 2022-02-25

研究纳入1774名接种BNT162b2 mRNA疫苗的医护人员,各取20名高抗体滴度者和低抗体滴度者分析外周血单个核细胞。接种前B细胞比例较高与较高抗体滴度相关,其中初始和过渡型B细胞频率与高抗体滴度正相关,晚期记忆B细胞和浆母细胞频率与低抗体滴度相关,接种后活化CD8+ T细胞频率的倍数变化也与高抗体滴度相关。

要点

  • 接种前B细胞比例较高与接种后较高抗体滴度相关。
  • 初始和过渡型B细胞频率与较高抗体滴度正相关。
  • 晚期记忆B细胞和浆母细胞频率与较低抗体滴度相关。

核心结论

  • 接种前B细胞比例较高、初始和过渡型B细胞频率较高以及接种后活化CD8+ T细胞频率倍数变化较大与较高抗体滴度相关,而晚期记忆B细胞和浆母细胞频率较高与较低抗体滴度相关。

研究设计与样本

  • 从1774名接种BNT162b2 mRNA疫苗的医护人员中,各选取20名高抗SARS-CoV-2抗体滴度者和20名低抗体滴度者,分析其外周血单个核细胞(PBMCs)。

主要发现

  • 接种前B细胞比例较高与较高抗体滴度相关。
  • B细胞中初始和过渡型B细胞频率与较高抗体滴度正相关。
  • 晚期记忆B细胞和浆母细胞频率与较低抗体滴度相关。
  • 接种后活化CD8+ T细胞频率的倍数变化与高抗体滴度相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Predictive clinical factors associated with favorable responses to BNT162b2 mRNA vaccine against SARS-CoV-2 have been reported in some studies; however, there is a subgroup with low antibodytiters without well-known clinical factors reducing antibody responses. To clarify the immunological backgrounds that underlie the difference in antibody responses, we analyzed peripheral blood mononuclear cells (PBMCs) of each 20 individuals with a high anti-SARS-CoV-2 antibody titer and a low antibody titer out of 1774 healthcare workers who received BNT162b2 mRNA vaccine. A higher percentage of B cells before vaccination was associated with a higher antibody titer. Among B cells, naïve and transitional B cell frequencies were positively correlated with a higher antibody titer, whereas the frequencies of late memory B cells and plasmablasts were associated with a lower antibody titer. Fold change in the frequency of activated CD8+ T cells upon vaccination was also correlated with high antibody titers.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kageyama T, Tanaka S, Etori K, et al. Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2. Vaccine. 2022. PMID: 35241300. doi:10.1016/j.vaccine.2022.02.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。